Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525260-18-00

Enrollment

Registered

2026-07-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

Number of participants with PPMS and SPMS who experience significant (>= 20%) worsening in their T25FW performance at 12 months compared to a baseline measurement.

Interventions

DRUGIndapamide Tablets 2.5mg

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of participants with PPMS and SPMS who experience significant (>= 20%) worsening in their T25FW performance at 12 months compared to a baseline measurement.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 9, 2026